Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial (2020)

First Author: Andrew R. Pettitt
Attributed to:  MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3324/haematol.2019.230805

PubMed Identifier: 32054653

Publication URI: http://europepmc.org/abstract/MED/32054653

Type: Journal Article/Review

Parent Publication: Haematologica

Issue: 12

ISSN: 0390-6078